Xenon Pharmaceuticals has temporarily paused enrolment of new patients in Phase III trials of azetukalner for major depressive disorder and bipolar depression. The 17 September measure followed a review of neuropsychiatric adverse events and talks with the independent data safety monitoring board.

Reported effects included confusion, speech difficulties, coordination problems and a small number of psychosis cases. The company says the events fit the molecule’s known profile but had not appeared in the same way in the mid-stage X-NOVA study. Patients already enrolled remain on study, including open-label extensions.

Xenon is examining dose changes. The pause is described as voluntary and, by design, temporary. It is not a withdrawal of the molecule and not a verdict on efficacy.

The focal-seizure programme is not included. On the same day the company filed an FDA application for azetukalner in focal seizures. The two files should not be mixed: a psychiatry enrolment pause does not, by itself, settle the epilepsy application.

Azetukalner remains experimental in depression. It is not an approved treatment for that indication. Clinical decisions for enrolled patients sit with investigators and the protocol, not with a headline.

This article is not medical advice. The final benefit–risk judgement depends on further data and regulators.

The picture shows a pharmaceutical laboratory setting, not a box of an authorised medicine and not an identifiable patient.

Image: researcher in a laboratory, NIH / Wikimedia Commons, public domain (Diane A. Reid). An archive frame, not the Xenon trials. Cropped to 16:9.

Source consulted: Reuters — Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns; Xenon Pharmaceuticals — Azetukalner NDA for focal seizures and psychiatry programme update.